View Cart  

FDA Wants Comments on Program for Longer New Drug Reviews

The FDA is seeking drugmaker comment on an upcoming independent assessment of its new lengthened review program under the newly reauthorized Prescription Drug User Fee Act (PDUFA).

To View This Article:


Subscribe To The Executive Briefing Series

Buy This Article Now

Add this article to your cart for $40.00